All In Biotech

Drug Trial Radar · NCT06499688

A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

A Randomized, Double-blind, Placebo- and Active-controlled Parallel-group Multi-center Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 529 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

529

Actual

Start

Dec 28, 2023

Primary completion

Mar 29, 2024

Study completion May 31, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo- and active-controlled parallel-group multi-center phase III study to evaluate the efficacy and safety of Rcombinant botulinum neurotoxin type A for injection (YY001)) in the treatment of moderate to severe glabellar lines.

Conditions

  • Moderate to Severe Glabellar Lines

Interventions

  • Rcombinant botulinum neurotoxin type A for injection (YY001)Biological

    Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

  • OnabotulinumtoxinABiological

    Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

  • PlaceboBiological

    Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The 4th week after treatment, the composite response rate on both the investigator's assessment and the participant's self-assessment concurrently of GL severity at maximal frown.Time frame: The 4th week after treatment
  2. At the 1st week, 8th week, and 12th week after treatment, the composite response rate on both the investigator's assessment and the participant's self- assessment concurrently of GL severity at maximal frown.Time frame: At the 1st week, 8th week, and 12th week after treatment

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

  • Peking Union Medical College Hospital , Chinese Academy of Medical Sciences

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Plastic Surgery Hospital, Chinese Academy of Medical Science

    Beijing, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • Guangdong Second People's Hospital

    Guangzhou, Guangdong, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Second Affiliated Hospital Of Xi'an Jiaotong University

    Xian, Shanxi, China

  • West China School of Medicine/West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.